Amyloid Beta Peptide Processing, Insulin Degrading Enzyme, and Butyrylcholinesterase

Overview

Journal Neurochem Res

Specialties Chemistry
Neurology

Date 2001 Aug 10

PMID 11495357

Citations 2

Authors

A S Balasubramanian

Affiliations

Soon will be listed here.

Abstract

Amyloid beta peptide implicated in Alzheimers disease is cleaved by insulin degrading enzyme (IDE). Abnormal cholinesterases similar to butyrylcholinesterase (BChE) are found in Alzheimer brain. The similarities between IDE and BChE (which is known to have an arylacylamidase and a metallocarboxypeptidase-like activity) such as their zinc metalloenzyme nature, their localization in glia and their ability to bind amyloid peptide in Alzheimers disease raise interesting questions.

Citing Articles

Unwinding Complexities of Diabetic Alzheimer by Potent Novel Molecules.

Gupta S, Nair A, Jhawat V, Mustaq N, Sharma A, Dhanawat M Am J Alzheimers Dis Other Demen. 2020; 35:1533317520937542.

PMID: 32864980 PMC: 10623924. DOI: 10.1177/1533317520937542.

Insulin resistance and Alzheimer's disease.

de la Monte S BMB Rep. 2009; 42(8):475-81.

PMID: 19712582 PMC: 4600067. DOI: 10.5483/bmbrep.2009.42.8.475.

References

Wright C, Geula C, Mesulam M . Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol. 1993; 34(3):373-84. DOI: 10.1002/ana.410340312. View

TUNE L, Gucker S, Folstein M, Oshida L, Coyle J . Cerebrospinal fluid acetylcholinesterase activity in senile dementia of the Alzheimer type. Ann Neurol. 1985; 17(1):46-8. DOI: 10.1002/ana.410170111. View

Lehmann D, Nagy Z, Litchfield S, Borja M, Smith A . Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease. Hum Genet. 2000; 106(4):447-52. DOI: 10.1007/s004390000277. View

Smith M, Perry G . Alzheimer disease: an imbalance of proteolytic regulation?. Med Hypotheses. 1994; 42(4):277-9. DOI: 10.1016/0306-9877(94)90132-5. View

Wright C, Guela C, Mesulam M . Protease inhibitors and indoleamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer disease. Proc Natl Acad Sci U S A. 1993; 90(2):683-6. PMC: 45728. DOI: 10.1073/pnas.90.2.683. View

Vekrellis K, Ye Z, Qiu W, Walsh D, Hartley D, Chesneau V . Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci. 2000; 20(5):1657-65. PMC: 6772918. View

Ashall F, Goate A . Role of the beta-amyloid precursor protein in Alzheimer's disease. Trends Biochem Sci. 1994; 19(1):42-6. DOI: 10.1016/0968-0004(94)90173-2. View

Grubber J, Saunders A, Scott W, Martin E, Haynes C, Conneally P . Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K). Neurosci Lett. 1999; 269(2):115-9. DOI: 10.1016/s0304-3940(99)00426-7. View

Geula C, Mesulam M . Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis Assoc Disord. 1995; 9 Suppl 2:23-8. DOI: 10.1097/00002093-199501002-00005. View

10.

Jensen F, Schwartz M, Viby-Mogensen J . Identification of human plasma cholinesterase variants using molecular biological techniques. Acta Anaesthesiol Scand. 1995; 39(2):142-9. DOI: 10.1111/j.1399-6576.1995.tb04033.x. View

11.

Lehmann D, Johnston C, Smith A . Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet. 1997; 6(11):1933-6. DOI: 10.1093/hmg/6.11.1933. View

12.

Checler F . Processing of the beta-amyloid precursor protein and its regulation in Alzheimer's disease. J Neurochem. 1995; 65(4):1431-44. DOI: 10.1046/j.1471-4159.1995.65041431.x. View

13.

Qiu W, Walsh D, Ye Z, Vekrellis K, Zhang J, Podlisny M . Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem. 1998; 273(49):32730-8. DOI: 10.1074/jbc.273.49.32730. View

14.

Balasubramanian A, Bhanumathy C . Noncholinergic functions of cholinesterases. FASEB J. 1993; 7(14):1354-8. DOI: 10.1096/fasebj.7.14.8224608. View

15.

George S, Balasubramanian A . The identity of the serotonin-sensitive aryl acylamidase with acetylcholinesterase from human erythrocytes, sheep basal ganglia and electric eel. Eur J Biochem. 1980; 111(2):511-24. DOI: 10.1111/j.1432-1033.1980.tb04967.x. View

16.

Kurochkin I . Amyloidogenic determinant as a substrate recognition motif of insulin-degrading enzyme. FEBS Lett. 1998; 427(2):153-6. DOI: 10.1016/s0014-5793(98)00422-0. View

17.

Rao R, Balasubramanian A . The peptidase activity of human serum butyrylcholinesterase: studies using monoclonal antibodies and characterization of the peptidase. J Protein Chem. 1993; 12(1):103-10. DOI: 10.1007/BF01024921. View

18.

Wagner S, Munoz B . Modulation of amyloid beta protein precursor processing as a means of retarding progression of Alzheimer's disease. J Clin Invest. 1999; 104(10):1329-32. PMC: 409850. DOI: 10.1172/JCI8729. View

19.

Atack J, May C, Kaye J, Kay A, Rapoport S . Cerebrospinal fluid cholinesterases in aging and in dementia of the Alzheimer type. Ann Neurol. 1988; 23(2):161-7. DOI: 10.1002/ana.410230209. View

20.

Geula C, Mesulam M . Special properties of cholinesterases in the cerebral cortex of Alzheimer's disease. Brain Res. 1989; 498(1):185-9. DOI: 10.1016/0006-8993(89)90419-8. View